Factors associated with HPV and other self-reported STI coinfections among sexually active Brazilian young adults: cross-sectional nationwide study

Natalia Luiza Kops, Marina Bessel, Jaqueline Driemeyer Correia Horvath, Carla Domingues, Flávia Moreno Alves de Souza, Adele Schwartz Benzaken, Gerson Fernando Mendes Pereira, Ana Goretti Kalume Maranhão, Luisa Lina Villa, Barbara Mello, Eliana Marcia Wendland

ABSTRACT

Objectives To analyse factors associated with genital human papillomavirus (HPV) and other self-reported sexually transmitted infection (STI) coinfections among women and men aged 16–25 years from Brazil.

Design A cross-sectional, nationwide, multicentre study.

Setting 119 primary healthcare centres between September 2016 and November 2017.

Participants 6388 sexually active young adults were enrolled by trained health professionals.

Primary outcome measure Genital HPV and other self-reported STI coinfections.

Results Of 3512 participants with valid data for genital HPV and (STI)-positive status, 276 (9.60%, 95% CI 7.82% to 11.36%) had HPV/STI coinfection. Among men, HPV/STI coinfection was more prevalent than HPV infection alone. Among HPV-positive participants, the percentage of subjects who reported having another STI was highest for gonorrhoea at 4.24% (95% CI 2.67% to 5.81%), followed by syphilis, herpes and HIV. Smoking, drug use and ever having a same-sex sexual experience were risk factors that were uniquely associated with HPV/STI coinfection compared with HPV infection alone.

Conclusions The results identified a low prevalence of self-reported STIs, but in participants with at least one STI, the prevalence of HPV was high. These results reinforce the importance of implementing strategies to prevent risky behaviours among Brazilian young adults.

INTRODUCTION

Sexually transmitted infections (STIs) are one of the most common global health problems; more than 1 million STIs are estimated to be acquired daily worldwide. Human papillomavirus (HPV) infection is one of the most prevalent STIs, affecting nearly half of the population in some age groups in countries such as the USA and Brazil.

HPV is a group of more than 150 related viruses, and at least 13 types are considered oncogenic, presenting a higher risk or probability of persistent infections and being associated with precursor cancer lesions. Although most HPV infections do not cause symptoms, persistent HPV infection can cause cervical cancer in women. This cancer is the fourth-most common cancer among women, and 99% of cases are linked to genital infection with HPV. Furthermore, there is growing evidence that HPV is a key factor in the development of other anogenital cancers (anal, vulvar, vaginal and penile cancers) as well as head and neck cancers.

Since high-risk strains of HPV is a necessary but not a sufficient cause of cervical cancer other biological, behavioural and environmental cofactors have been implicated in the development of HPV-associated cancers. Studies establishing an association between HPV infection and other STIs may help to improve understanding of the role of these coinfections in the development of cervical cancer. Interactions among HPV, other viruses and microbes that share a similar epithelial niche could enhance HPV replication and infection persistence and accelerate cancer progression.
Precise estimates of STI coinfection are limited, especially in the general population. The availability of epidemiological data on HPV and STI coinfection in Brazilian young adults is essential for the development of successful strategies for STI prevention, diagnosis and management in the country. According to this epidemiological scenario, the present study aimed to analyse factors associated with genital HPV and other self-reported STI coinfections among women and men aged 16–25 years from Brazil.

METHODS
This is a nationwide, cross-sectional, multicentre study of sexually active young adults who use the public health system (POP-Brazil Study). Participants from 119 designated public primary healthcare units of the 26 state capitals and the Federal District of Brazil were invited to participate from September 2016 to November 2017. Primary healthcare professionals were personally trained by the central study coordinator for data acquisition.

The following exclusion criteria were applied: pregnant women, those who delivered a baby in the last 3 months, who had undergone a hysterectomy or trachelectomy and who had any history of cervical intraepithelial neoplasia grade 2 or higher. Participants vaccinated for HPV were excluded from the analyses.

The study was approved by the Ethics Committee on Human Research (Hospital Moinhos de Vento—protocol no. 1607032) and by the recruitment sites. All participants provided written consent.

Patient and public involvement
Patients and the public were not involved in the protocol development.

Study procedures
All individuals answered a standardised questionnaire based on validated instruments that assessed sociodemographic characteristics, sexual behaviours, smoking status and history of STIs. Participants were asked about their income, education level, age at first intercourse, age at first pregnancy, age of partner at first sexual intercourse, number of sexual partners in the last year, whether they had ever had a same-sex sexual experience, current condom use and condom use at first sexual intercourse. To evaluate alcohol and drug consumption, we asked about patterns of use throughout life, use in recent years and current use.

Cervical samples were obtained using a digene HC2 DNA Collection Device (Qiagen), and penile samples (penile shaft, glans penis/coronal sulcus, scrotum) were obtained using a Dacron swab (Qiagen) previously humidified in sterile saline solution. All biological samples were maintained at room temperature (15°C to 25°C) according to the manufacturer’s instructions and transported to a central laboratory for specimen processing.

HPV detection and typing were performed using the Linear Array HPV Genotyping Test (Roche Diagnostics), which is based on PCR amplification (fragment of 450 base pairs of the polymorphic region of the L1 gene of HPV), followed by specific hybridisation and colourimetric detection, in a certified laboratory. The amplification of human β-globin (biotinylated primers GH2O and PC04, 268 base-pair fragments) was used as an internal control.

To characterise other STIs, we asked participants if they had ever been diagnosed with syphilis, gonorrhoea and/or herpes. We also asked if they had ever been tested for HIV and for the results of any previous tests. Additionally, participants were invited to undergo a rapid HIV test. Individuals who reported having STIs had a positive HIV test result in the past or had a positive HIV rapid test result at the time of the interview were considered positive.

Unanswered questions were considered missing values in the analysis. Those who were never tested for HIV and who did not take a rapid or laboratorial test at the time of the interview were also considered to have missing values for HIV.

Participants were categorised into three groups according to their infection status: HPV only, HPV/STI coinfection or STI only. HPV only was defined as having just HPV without other STIs; HPV/STI coinfection was defined as having any one type of HPV plus any one of the four STIs and STI only was defined as having one or more of the four STIs without HPV.

The sample size was based on the main research project aim, namely, establishing the prevalence of HPV in Brazil. The number of samples were equally divided in all regions to maximise diversity in less-populated areas.

Statistical analysis
Categorical variables were summarised using absolute frequencies and percentages, while continuous variables were analysed using means and CIs. To compare proportions, a 2 test was used. For differences among the three infection groups, Poisson regression models with robust variance were estimated to compare those with HPV/STI coinfection to those infected by HPV only. All variables with p<0.20 were included hierarchically (sociodemographic and socioeconomic, behavioural and sexual characteristics, consecutively) in a multivariate model. The interactions among effect modifiers were analysed.

To adjust the distribution of the sample to the study population, we weighted the measures by the size of the population in each capital and by sex. Therefore, all results are reported as weighted. Statistical analysis was performed using SAS software V.9.4 (Statistical Analysis System, SAS Institute), and statistical significance was defined as p<0.05.
In total, 6388 participants (5268 women) were included in the study (figure 1). The predominant socioeconomic index was class C (55.46%, 95% CI 53.30 to 57.62), and the predominant skin colour was pardo/brown (56.97%, 95% CI 54.77 to 59.16). The analysis was restricted to HPV-positive participants and those that provided information on STI status (see online supplementary file 1). Among the 3512 participants, 276 (9.60%, 95% CI 7.82 to 11.36) had HPV/STI coinfection. Of these individuals, the majority (87.71%) reported having only one STI aside from HPV.

Among women, HPV infection only was more prevalent than HPV/STI coinfection. In contrast, HPV/STI coinfection was more prevalent than HPV infection only among men. Participants who reported having other STIs only were older than those who reported having HPV infection only, but no age difference was found in relation to HPV/STI coinfection. Furthermore, sociodemographic and socioeconomic characteristics, such as skin colour, income and education level were similar between the two groups. Participants with HPV/STI coinfection were younger at first sexual intercourse than those with HPV only (14.90 years, 95% CI 14.46 to 15.34 vs 15.29 years, 95% CI 15.16 to 15.43). On the other hand, the age of the partner at first sexual intercourse was higher in the HPV/STI coinfection group than in the other groups (table 1).

Among the HPV-positive participants, gonorrhoea was the most prevalent reported infection 4.24% (95% CI 2.67% to 5.81%), followed by syphilis, herpes and HIV (figure 2). When we look for the prevalence of HPV among all participants who reported STI, people with HIV presented the higher HPV positivity, with 25 positive cases of HPV among 33 HIV cases (85.41%, 95% CI 69.89% to 100.00%). The second STI most associated with HPV was gonorrhoea: 76 of 133 cases (62.77%, 95% CI 46.66% to 78.88%), followed by herpes (62.23%, 95% CI 46.55% to 77.92%) and syphilis (59.56%, 95% CI 49.07% to 70.05%) (data not shown).

The prevalence of HPV/STI coinfection varied by sex. More men had HPV/gonorrhoea and HPV/HIV coinfection than women (figure 3). Regarding STI treatment, 85.97% (95% CI 82.43% to 89.52%) of participants searched for health professionals, 7.49% (95% CI 4.59% to 10.39%) did nothing, and 6.53% (95% CI 4.28% to 8.77%) were self-medicated; no significant sex differences emerged (p=0.632) (data not shown).

A multivariate analysis was performed to verify the variables associated with HPV/STI coinfection. When adjusted for sociodemographic and socioeconomic variables, the male sex was associated with coinfection. However, after the inclusion of behavioural and sexual variables, sex was no longer significant. In the full model (model 3), smoking (prevalence ratio (PR)=1.64, 95% CI 1.03 to 2.61), illegal drug use (PR=1.58, 95% CI 1.05 to 2.39) and same-sex sexual experience (PR=2.15, 95% CI 1.27 to 3.62) were variables that were uniquely associated with coinfection compared with those associated with HPV infection only (table 2). However, the estimated indirect effect mediated by gender was 0.007 (p=0.004), and 10.55% of the total effect of same-sex sexual experience was mediated by sex. Education and socioeconomic class were not associated with the presence of coinfection.

RESULTS

In total, 6388 participants (5268 women) were included in the study (figure 1). The predominant socioeconomic index was class C (55.46%, 95% CI 53.30 to 57.62), and the predominant skin colour was pardo/brown (56.97%, 95% CI 54.77 to 59.16). The analysis was restricted to HPV-positive participants and those that provided information on STI status (see online supplementary file 1). Among the 3512 participants, 276 (9.60%, 95% CI 7.82 to 11.36) had HPV/STI coinfection. Of these individuals, the majority (87.71%) reported having only one STI aside from HPV.

Among women, HPV infection only was more prevalent than HPV/STI coinfection. In contrast, HPV/STI coinfection was more prevalent than HPV infection only among men. Participants who reported having other STIs only were older than those who reported having HPV infection only, but no age difference was found in relation to HPV/STI coinfection. Furthermore, sociodemographic and socioeconomic characteristics, such as skin colour, income and education level were similar between the two groups. Participants with HPV/STI coinfection were younger at first sexual intercourse than those with HPV only (14.90 years, 95% CI 14.46 to 15.34 vs 15.29 years, 95% CI 15.16 to 15.43). On the other hand, the age of the partner at first sexual intercourse was higher in the HPV/STI coinfection group than in the other groups (table 1).

DISCUSSION

In this study, the prevalence of HPV/STI coinfection among 3512 Brazilian young adults was analysed. This study included a nationwide sample that represented a large and diverse population and showed important data on risk factors associated with HPV/STI coinfection. HPV/gonorrhoea was the most prevalent coinfection, followed by HPV/syphilis. Smoking, drug use and ever having a same-sex sexual experience were risk factors that were uniquely associated with coinfection compared with those associated with HPV infection only (table 2). However, the estimated indirect effect mediated by gender was 0.007 (p=0.004), and 10.55% of the total effect of same-sex sexual experience was mediated by sex. Education and socioeconomic class were not associated with the presence of coinfection.
Despite the low frequency of self-reported STIs during the short sexual life of the study participants, the prevalence of genital HPV was high among participants with STIs. Genital infections with HPV are dynamic, usually occurring soon after acquisition of a new sexual partner and regressing after immune recognition, although occasionally persisting for years. Furthermore, with the presence of any STI, HPV infection is even more prevalent, and a history of prior STIs has been linked to a reduced ability to clear HPV or an increased risk of acquisition of HPV infection.19

Among HPV-infected women, concurrent infections with chlamydia, gonorrhoea and herpes have been linked to the persistence of HPV and an increased risk of cervical neoplasia.20 HIV predisposes affected women to acquire HPV infections and also promotes the development of cervical neoplasia through the upregulation of HPV oncoprotein expression.21 The prevalence of HPV in HIV-positive

| Table 1 Characteristics of the participants according to the presence of HPV infection and other self-reported STIs in the POP-Brazil Study, 2016–2017 |
| Variables | Total 3512 | HPV only 3087 (84.80) | HPV/STI coinfection 276 (9.60) | STI only 149 (5.60) |
| Sex | | | | |
| Female | 2891 | 2587 (66.27)*† | 196 (52.80)* | 108 (45.80)† |
| Male | 621 | 500 (33.73)*† | 80 (47.20)* | 41 (54.20)† |
| Age (years) | | | | |
| <22 | 2005 | 1799 (56.36) | 145 (54.37) | 61 (40.67) |
| ≥22 | 1507 | 1288 (43.64)† | 131 (45.63) | 88 (59.33)† |
| Race/skin colour | | | | |
| White | 808 | 696 (21.66) | 74 (24.07) | 38 (20.44) |
| Black | 569 | 496 (17.07) | 44 (17.18) | 29 (20.72) |
| Pardo/brown | 2038 | 1808 (59.26) | 149 (56.03) | 81 (57.86) |
| Others | 83 | 74 (2.01) | 8 (2.72) | 1 (0.98) |
| Relationship status | | | | |
| With a partner | 2628 | 2324 (75.11) | 204 (69.42) | 100 (69.24) |
| Without a partner | 884 | 763 (24.89) | 72 (30.58) | 49 (30.76) |
| Current condom use | 1773 | 1583 (51.76)† | 128 (46.35) | 62 (33.69)† |
| Condom use at first sexual intercourse | 2246 | 2001 (60.07) | 161 (59.05) | 84 (54.57) |
| Ever been pregnant | 1294 | 1114 (43.94)† | 114 (51.44) | 66 (63.87)† |
| Ever had same-sex sexual experience | 158 | 122 (5.25)*† | 20 (18.29)* | 16 (24.41)† |
| Alcohol consumption | 2592 | 2250 (73.56)* | 231 (86.04)* | 111 (75.53) |
| Drug use | 1009 | 823 (29.79)* | 133 (56.16)† | 53 (33.88)† |
| Smoking status | | | | |
| Non-smoker | 2326 | 2099 (64.74)* | 139 (42.09)*† | 88 (63.21)† |
| Smoker | 505 | 396 (14.91)* | 75 (33.01)* | 34 (21.82) |
| Ex-smoker | 681 | 592 (20.35) | 62 (24.90) | 27 (14.97) |
| Age at first sexual intercourse (years) | 3441 | 15.29 (15.16–15.43)* | 14.90 (14.46–15.34)* | 14.74 (14.15–15.33)† |
| Age of partner at first sexual intercourse (years) | 3141 | 19.09 (18.78–19.40)* | 18.33 (17.61–19.05)* | 19.84 (17.55–22.13)‡ |
| Age at first pregnancy (years) | 1301 | 16.88 (16.57–17.20) | 17.28 (16.65–17.92) | 16.46 (16.49–18.23) |
| Number of sexual partners in the last year | | | | |
| ≥2 | 227 | 952 (34.14)*† | 129 (53.20)* | 56 (53.04)† |
| <2 | 1137 | 2010 (65.86)*† | 128 (46.80)* | 89 (46.96)† |

*Significant differences between HPV only and HPV/STI coinfection groups (P<0.05).
† Significant differences between HPV only and STI only groups (P<0.05).
‡ Significant differences between STI only and HPV/STI coinfection groups (P<0.05).
Results of Poisson regression analysis and Tukey’s post-hoc multiple comparison tests.
HPV, human papillomavirus; STI, sexually transmitted infection.

and in target populations, such as those who are pregnant,17 homosexual18 or HIV positive.7
young adults (85.4%) was higher than that in Puerto Rico (50.3%) and Italy (48%) but similar to that in other previous studies in Brazil (68.1% and 73.5%) and sub-Saharan Africa (72.2%). In contrast, the low rate of HPV/HIV coinfection could be explained by the age of the study population because HPV is acquired via sexual exposures; newly sexually active adolescents and young adults have the highest risk of HPV acquisition, while young adults have not had sufficient time to develop other STIs. The same phenomenon occurs with HPV/herpes coinfection, which was also not as common in this study as in other studies, in addition to robust epidemiological evidence suggesting that HPV could be a possible cofactor in cervical carcinogenesis.

### Table 2

|                  | Model 1            | Model 2       | Model 3       |
|------------------|--------------------|---------------|---------------|
| **Prevalence ratio (95% CI)** |                    |               |               |
| **Male sex**     | 1.67 (1.14; 2.43)  | 1.20 (0.85; 1.69) | 1.09 (0.71; 1.66) |
| **Education level** |                    |               |               |
| Elementary school (complete or incomplete) | 1.13 (0.60; 2.12) | 0.87 (0.48; 1.60) | 0.92 (0.44; 1.93) |
| Secondary school (complete or incomplete) | 1.07 (0.63; 1.82) | 1.04 (0.63; 1.72) | 1.25 (0.67; 2.33) |
| Graduate education (complete or incomplete) | 1                  | 1             | 1             |
| **Socioeconomic class** |                    |               |               |
| A–B              | 1.53 (0.86; 2.71)  | 1.69 (0.96; 2.98) | 1.52 (0.80; 2.90) |
| C                | 1.36 (0.72; 2.56)  | 1.49 (0.79; 2.82) | 1.46 (0.71; 3.01) |
| **Relationship status** |                    |               |               |
| With a partner   | 1                  | 1             | 1             |
| Without a partner | 1.25 (0.83; 1.89) | 1.19 (0.81; 1.75) | 1.12 (0.74; 1.69) |
| **Smoking status** |                    |               |               |
| Non-smoker       | 1                  | 1             | 1             |
| Smoker           | 1.77 (1.17; 2.67)  | 1.64 (1.03; 2.61) | 1.03 (0.61; 1.75) |
| Ex-smoker        | 1.17 (0.76; 1.80)  | 1.27 (0.79; 2.05) | 1.58 (1.05; 2.39) |
| Alcohol consumption | 1.42 (0.87; 2.32) | 1.03 (0.61; 1.75) |               |
| Drug use         | 1.97 (1.38; 2.82)  | 1.58 (1.05; 2.39) |               |
| **Condom use at last sexual intercourse** | 0.92 (0.62; 1.35) |               |               |
| More than two partners in the last year | 1.43 (0.96; 2.14) |               |               |
| Age at first sexual intercourse | 0.96 (0.86; 1.06) |               |               |
| Ever had same-sex sexual experience | 2.15 (1.27; 3.62) |               |               |

Model 1: Sex, education level, socioeconomic class and relationship status.
Model 2: Model 1+smoking status, alcohol consumption and drug use.
Model 3: Model 2+condom use at last sexual intercourse, more than two partners in the last year, age at first sexual intercourse and ever had same-sex experience.
HPV, human papillomavirus; STI, sexually transmitted infection.
It was evident in the present study that smoking, drug use and ever having a same-sex sexual experience were uniquely associated with the presence of HPV/STI coinfection. Smoking cigarettes contributes to cervical cancer and has already been associated with the prevalence, incidence and persistence of HPV. Few studies have examined the relationship between drug use and HPV infection, but cocaine use has been associated with an increased risk of detection of both prevalent and incident oncogenic HPV infection, suggesting that the response to HPV infection might be altered by cocaine. Condom use seems not to interfere with the prevalence of HPV in drug users. Furthermore, same-sex sexual experience as a risk factor can be explained by the extended heteronormality in the healthcare system (and at Brazilian society) and unequal access to health services. No significant differences were found in relation to sociodemographic characteristics, despite the fact that STIs disproportionately affect low-income and middle-income countries.

Although the rates of more than one STI associated with HPV were relatively low in the present study, the presence of one STI is itself a risk factor for contracting another STI. This is probably attributable to the impairment of the immune response by STIs, such as the presence of common risk factors. Another study of South African women showed that male sexual partners’ STI histories may be more important than women’s lifetime number of sexual partners. This factor was not analysed in the present study, but it could be important for the developing medical and behavioural interventions that include STI screening and treatment programmes, information on condom use and HPV vaccination for both women and men to reduce the prevalence of HPV/STI coinfection.

This is the first study to assess factors associated with HPV and other self-reported STI coinfections in men and women in Brazil. The sociodemographic characteristics of the study participants were similar to those of the Brazilian population. Nevertheless, some limitations should be noted. We use the term coinfection even for infections (syphilis, gonorrhoea or herpes) that could be diagnosed and treated in the past. The infections may have occurred in the past and thus may not reflect the actual STI status. The cases of STIs were self-reported (with the exception of HIV), and many STIs have no signs or symptoms, both of which may have contributed to an underestimation of STI prevalence. Previous study with the same sample age estimated that 7% of all sexually experienced young men resided sexually transmitted disease self-reports over time. We use Roche Linear Array HPV genotyping, and this test have a consistently high sensitivity and specificity (91.7% to 94.3%, respectively).

The results identified a low prevalence of self-reported STIs, but in participants with at least one infection, the prevalence of HPV was high. Smoking, drug use and same-sex sexual experience were associated with HPV/STI coinfection among Brazilian young adults. These findings reinforce the importance of implementing strategies to prevent risky behaviours. This knowledge may contribute to improving prevention strategies and treatment.

**Author affiliations**

1. WHO. Global health sector strategy on Sexually Transmitted Infections, 2016-2021. World Health Organization Department of Reproductive Health and Research, 2016.
2. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. *JAMA* 2007;297:813.
3. Ayles AR, Silva GA. Cervical HPV infection in Brazil: systematic review. *Rev Saúde Pública* 2010;44:963-74.
4. McCulligan G, Kruszon-Moran D, Markowitz LE, et al. *Progress in the prevention of HPV in Adults Aged 18-69*; United States, 2011-2014. NCHS Data Brief 2017;1-8.
5. INCA - Instituto Nacional de Câncer - Estimativa 2018 - Introdução. http://www.inca.gov.br/estimativa2018/introducao.asp (Accessed 26 Apr 2018).
6. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. *Summary Report* 2017:27.
7. Lin C, Franceschi S, Clifford GM. Human papillomavirus types (from infection to cancer in the anus, according to sex and HPV status: a systematic review and meta-analysis. *Lancet Infect Dis* 2018;18:198-206.
8. Castellsagué X, Bosch FX, Muñoz N. Environmental co-factors in HPV carcinogenesis. *Virus Res* 2002;89:191–9.
9. Wendland EM, Cairoló J, Domingues C, et al. POP-Brazil study protocol: a nationwide cross-sectional evaluation of the prevalence and genotype distribution of human papillomavirus (HPV) in Brazil. *BMJ Open* 2018;8:e021170.
10. Bastos Fl, Barata R de CS, Aquino EM, et. al. Caracterização sexual e percepções sobre HIV/Aids no Brasil. *Rev Saúde Pública* 2008;42:1-2.

**REFERENCES**
22. Ortiz AP, Tamayo V, Scorsone A, et al. Human papillomavirus in the HIV-infected. *Int J Gynaecol Obstet* 2012;117:211–6.

23. Tartaglia E, Falasca K, Vecchiet J, et al. Prevalence of HPV infection among HIV-positive and HIV-negative women in Central/Eastern Italy: Strategies of prevention. *Oncof Lett* 2017;14:

24. Araújo AC, Carvalho NO, Teixeira NC, et al. Incidence of cervical intraepithelial neoplasia in a cohort of HIV-infected women. *Int J Gynaecol Obstet* 2012;117:211–6.

25. Badiol RM, Dias MC, Stuqui B, et al. Detection and genotyping of human papillomavirus (HPV) in HIV-infected women and its relationship with HPV/HIV co-infection. *Medicine* 2018;97:e9545.

26. Veldhuijzen NJ, Braunstein SL, Vyankondondera J, et al. The epidemiology of human papillomavirus infection in HIV-positive and HIV-negative high-risk women in Kigali, Rwanda. *BMJ Infect Dis* 2011;11:333.

27. Burchell AN, Winer RL, de Sanjose S, et al. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. *Vaccine* 2006;24 Suppl 3:S52–S61.

28. Smith JS, Herrero R, Bosetti C, et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. *J Natl Cancer Inst* 2002;94:1604–13.

29. Schabath MB, Villa LL, Lazzcano-Ponce E, et al. Smoking and human papillomavirus (HPV) infection in the HPV in Men (HIM) study. *Cancer Epidemiol Biomarkers Prev* 2012;21:102–10.

30. Minkoff H, Zhong Y, Strickler HD, et al. The relationship between cocaine use and human papillomavirus infections in HIV-seropositive and HIV-seronegative women. *Infect Dis Obstet Gynecol* 2008:2008:1–7.

31. Dev D, Lo Y, Ho KY, et al. Incidence of and risk factors for genital human papillomavirus infection in women drug users. *J Acquir Immune Defic Syndr* 2006;41:527–9.

32. Logie CH, Lacome-Duncan A, Wang Y, et al. Sexual orientation differences in health and wellbeing among women living with hiv in canada: Findings from a national cohort study. *AIDS Behav* 2018;22:1987–2001.

33. Umemo M, Bradshaw CS, Hocking JS, et al. Sexually transmitted infections: challenges ahead. *Lancet Infect Dis* 2017;17:e235–e279.

34. Dariotis JK, Pleck JH, Sonenstein FL, et al. What are the consequences of relying upon self-reports of sexually transmitted diseases? Lessons learned about recanting in a longitudinal study. *J Adolesc Health* 2009;45:187–92.

35. Xu L, Östörbenk A, Poljak M, et al. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework. *J Clin Virol* 2018;98:37–42.